Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23467074 | 0.79 | CA1 (0.40) | CA1CA2CA4KMT2AMAPT | |
| Ammonia Solution, Strong SCHEMBL5192485 | 0.78 | CA1 (0.39) | CA1CA2CA4KMT2AMAPT | |
| SCHEMBL181970 | 0.76 | — | — | |
| SCHEMBL6912662 | 0.76 | — | — | |
| SCHEMBL1568359 | 0.76 | — | — | |
| SCHEMBL7871650 | 0.75 | CA1 (0.48) | CA1CA2CA4KMT2AMAPT | |
| SCHEMBL5194718 | 0.75 | CA1 (0.48) | CA1CA2CA4KMT2AMAPT | |
| SCHEMBL6916176 | 0.74 | KMT2A (0.52) | CA1CA2CA4KMT2AMAPT | |
| SCHEMBL9874961 | 0.74 | KMT2A (0.52) | CA1CA2CA4KMT2AMAPT | |
| Methylsulfanylmethane SCHEMBL15329055 | 0.73 | CA1 (0.36) | CA1CA2CA4KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2605772-B1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME INTERNAT AG (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-20150259284-A1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME INTERNATIONAL SA (CH) | 2015-09-17 | — | — | US | disclosed |
| US-9006460-B2 | Process for preparing aminocyclohexyl ether compounds | CARDIOME INTERNATIONAL AG (CH) | 2015-04-14 | — | — | US | disclosed |
| EP-2605772-A2 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130149751-A1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME INTERNATIONAL SA (CH) | 2013-06-13 | — | — | US | disclosed |
| WO-2012024100-A2 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259284-A1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CYP3A43, CYP4B1, CYP3A4 | CA1 2272/4885CA2 2293/4885CA4 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.